Travere Therapeutics (TVTX) Investor update summary

Strategic Collaboration and Licensing Agreement

• Exclusive licensing and collaboration agreement for civorebrutinib, granting development and commercialization rights outside China and select Asian countries, with collaboration on U.S. and global development plans.

• Everest Medicines receives $112.5 million upfront, with potential for up to ~$1.03 billion in milestone payments across up to five indications, and tiered royalties on future net sales.

• Agreement becomes effective upon satisfaction of customary conditions, including antitrust clearance, and is expected to close in Q3 2026.

• Collaboration leverages both companies' expertise to advance global development and commercialization.

Pipeline Expansion and Clinical Development

• Civorebrutinib is a next-generation, oral, covalent reversible BTK inhibitor with high selectivity and strong potency, targeting immune-mediated rare kidney diseases.

• Demonstrated proof of concept in Phase 1/2 trial for primary membranous nephropathy, showing ~90% reduction in anti-PLA2R autoantibody and ~80% reduction in proteinuria by week 36, sustained after treatment.

• Favorable safety profile with no clinically meaningful adverse events typical of BTK inhibitors; most common AEs were mild to moderate, with no liver safety signals or class-related adverse events observed in over 150 subjects.

• Planned evaluation in FSGS, MCD, IgA nephropathy, and potentially other indications, with upcoming data presentations and global development strategy to be clarified after transaction completion.

• Intends to align with Everest, FDA, and global regulators for next-stage clinical development, including pivotal studies in PMN and expansion to FSGS and other indications.

Market Opportunity and Portfolio Integration

• Civorebrutinib offers pipeline-in-a-product potential, expanding and diversifying the rare kidney disease portfolio alongside existing therapies such as FILSPARI and pegtibatinase.

• Over 130,000 diagnosed patients across pMN, immune-mediated FSGS, and MCD in key markets, with pMN having no approved treatments and significant unmet needs.

• Distinct B-cell acting mechanism complements existing nephroprotective therapies, supporting portfolio diversification and addressing heterogeneous patient needs.

• Multi-billion-dollar global commercial opportunity expected to drive long-term, durable revenue growth.